Recent patient data surrounding Retatrutide , specifically the 120 milligram formulation referred to as ZPHC, reveal a considerable benefit on physique loss and related chronic conditions . Experts believe that this dual acting , affecting both GLP-1 and GIP receptors , could represent a major breakthrough in the treatment of obesity and connected